These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 15922865)

  • 1. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
    Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y
    Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Williams NN; Kaiser LR; Croce CM
    Cancer Res; 2003 Jun; 63(12):3352-5. PubMed ID: 12810670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas.
    Hesson L; Bièche I; Krex D; Criniere E; Hoang-Xuan K; Maher ER; Latif F
    Oncogene; 2004 Mar; 23(13):2408-19. PubMed ID: 14743209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
    Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
    Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
    Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
    BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.
    Lerman MI; Minna JD
    Cancer Res; 2000 Nov; 60(21):6116-33. PubMed ID: 11085536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
    Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
    Dammann R; Li C; Yoon JH; Chin PL; Bates S; Pfeifer GP
    Nat Genet; 2000 Jul; 25(3):315-9. PubMed ID: 10888881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma.
    Riquelme E; Tang M; Baez S; Diaz A; Pruyas M; Wistuba II; Corvalan A
    Cancer Lett; 2007 May; 250(1):100-6. PubMed ID: 17084965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung cancer.
    Marsit CJ; Hasegawa M; Hirao T; Kim DH; Aldape K; Hinds PW; Wiencke JK; Nelson HH; Kelsey KT
    Cancer Res; 2004 Dec; 64(23):8702-7. PubMed ID: 15574780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors.
    Tischoff I; Markwarth A; Witzigmann H; Uhlmann D; Hauss J; Mirmohammadsadegh A; Wittekind C; Hengge UR; Tannapfel A
    Int J Cancer; 2005 Jul; 115(5):684-9. PubMed ID: 15704097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
    Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
    Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
    Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
    Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
    Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
    Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
    Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
    Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.